Newsroom
About
Aqualung Therapeutics Corporation is a Tucson -based early stage biotech company whose leadership are experienced life science executives and entrepreneurs with expertise in Precision Medicine, Drug Development, Drug Manufacturing and Commercialization. They are committed to exploring NAMPT as a key target and novel diagnostic to address the “unchecked inflammation” elicited by dysregulated innate immunity pathways in a variety of acute and chronic conditions with significant unmet therapeuti...
Aqualung Therapeutics Corporation is a Tucson -based early stage biotech company whose leadership are experienced life science executives and entrepreneurs with expertise in Precision Medicine, Drug Development, Drug Manufacturing and Commercialization. They are committed to exploring NAMPT as a key target and novel diagnostic to address the “unchecked inflammation” elicited by dysregulated innate immunity pathways in a variety of acute and chronic conditions with significant unmet therapeutic needs.
Press Contacts
Video
eNamptor™
View on Youtube
Resources (Files)
Bios
University of Arizona Endowed Merlin K. DuVal MD Professor of Medicine and an elected member of the National Academy of Medicine. Dr. Garcia is a internationally recognized physician-scientist with over 30 years of research experience in pulmonary disease and has led multi-billion dollar academic organizations.
https://cdn.filestackcontent.com/AILfKbYStWMdlo6rtF9R
A recognized global executive with success in sales, marketing and P&L leadership in the pharmaceutical/medical device and biotech industries. Mr. Miele was formally the Chief Commercial Officer at bioLytical Laboratories and Sucampo Pharmaceuticals Inc. He was also President of Sucampo Pharma Americas for 6 years. He was instrumental on some key licensing agreements for Sucampo, inclusive of the agreement with Abbott Japan, and also Takeda Pharmaceuticals (now Shire). He is actively part of the team ensuring proper execution of clinical development, manufacturing, licensing, capital funding, alliances, and ensuring Aqualung meets all critical milestones. He will be helping the company move toward accelerating the pipeline/platform technology and moving eNamptor™ toward commercialization.
https://cdn.filestackcontent.com/JvWrNelUSO5BnWWMHKNZ
Select Coverage
Apr 03, 2020
ABC News
Mar 22, 2020
Technology Networks
